FDA Clearance Tracker · K170557
GenePOC GBS LB
Last checked: Nov 20, 2026Latest source record: May 25, 2017 (this decision)Source: openFDAMethods & limitations
Decided
May 25, 2017
Substantially Equivalent
Time to decision
90 days
Received Feb 24, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class I
The decision
- FDA number
- K170557
- Device name
- GenePOC GBS LB
- Applicant
- Genepoc, Inc.
- Applicant location
- Quebec, CA
- Received
- Feb 24, 2017
- Decided
- May 25, 2017
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Nucleic Acid Amplification Assay System, Group B Streptococcus, Direct Specimen Test (NJR)
- Device class
- Class I
- Regulation
- 21 CFR 866.3740
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NJR. The earliest in FDA's data is K022504, decided Nov 18, 2002.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K170557
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Genepoc, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- GenePOC Carba510(k)
K190275 · Decided May 10, 2019 · 91 days after receipt
Device type: System, Nucleic Acid Amplification Test, Dna, Carbapenem Non-Susceptible Gram Negative Organism, Colony (PMY) · Laboratory Medicine & Pathology
- GenePOC Strep A510(k)
K183366 · Decided Mar 6, 2019 · 92 days after receipt
Device type: Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (PGX) · Laboratory Medicine & Pathology
- GenePOC CDiff510(k)
K172569 · Decided Nov 22, 2017 · 89 days after receipt
Device type: C. Difficile Toxin Gene Amplification Assay (OZN) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.